Biosymtec Medical, Inc.

Raising $5 Mil to complete final design, tooling and marketing rollout of revolutionary medical product.

Biosymtec Medical, Inc.

Biosymtec Medical is seeking a $5 million loan or equity funding to complete final design drawings for the production tooling and marketing rollout of the Kalabre, a product capable of detecting viral and bacterial infections before symptoms cause patients to go to hospitals. The product’s proprietary AI algorithm detects infections early enough for physicians, who are automatically alerted by the Biosymtec System, to prescribe antivirals and antibiotics for their patients when they are most effective.

Pre-clinical trial research studies: Kalabre’s proprietary early-detection technology was confirmed through research studies at five Hong Kong health clinics, the Tianjin Haihe Hospital, and a local Pennsylvania community.

Primary Markets: Certain patients, who are prone to infections, benefit from early detection. Therefore, our primary markets include COPD, asthma, and CHF patients, 45 million in the U.S. alone. The Kalabre and Biosymtec System will also play an important role in the detection and control of future pandemics.

Revenue Paradigm: Sales of Kalabres through specialist physicians will place them in the hands of patients to monitor themselves upon waking daily. Purchased Biosymtec smartphone Apps will permit subscribed physicians to view proprietary graphs forwarded by the Kalabre and get paid by the insurance carriers to review the graphs. Subscription revenues may exceed product sales.

Biosymtec Medical Management Team: Biosymtec Medical has assembled a team of seasoned medical-product professionals to operate the company.

Ready to Ask For Funding for your company?

Post a Funding Request

Biosymtec Medical, Inc. is no longer seeking funding.

Biosymtec Medical, Inc.

Key Facts